Patents by Inventor Yasuo Sekimori
Yasuo Sekimori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8920797Abstract: The present inventors discovered that stable and highly concentrated IgM solutions can be prepared by using, as an additive, a compound comprising a polyvalent cationic ion, such as magnesium chloride or arginine hydrochloride, to suppress IgM aggregation in solutions.Type: GrantFiled: July 24, 2009Date of Patent: December 30, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Yasuo Sekimori
-
Patent number: 8257703Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: GrantFiled: March 18, 2010Date of Patent: September 4, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Patent number: 8022191Abstract: The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.Type: GrantFiled: August 3, 2006Date of Patent: September 20, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Teruo Nakamura, Yasuo Sekimori, Minoru Machida, Hiromitsu Kawata, Hajime Miyamoto
-
Publication number: 20110070614Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Inventors: MASAYUKI TSUCHIYA, SHIGEYUKI IIJIMA, IZUMI SUGO, YASUO SEKIMORI, KENJU UENO, KIYOSHI HABU
-
Patent number: 7863042Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: GrantFiled: June 18, 2004Date of Patent: January 4, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu
-
Patent number: 7803914Abstract: The present inventors examined use of citric acid buffers for suppressing cryoprecipitation of IgM at a pH range and salt concentration suitable for storing IgM. As a result, the present inventors discovered that citric acid buffers significantly suppress cryoprecipitation.Type: GrantFiled: October 8, 2004Date of Patent: September 28, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Akira Hayasaka, Tomoyuki Igawa, Yasuo Sekimori
-
Publication number: 20100172899Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Patent number: 7709615Abstract: IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM.Type: GrantFiled: July 15, 2004Date of Patent: May 4, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Reiko Irie, Hiroyuki Tsunoda, Tomoyuki Igawa, Yasuo Sekimori, Masayuki Tsuchiya
-
Publication number: 20090285802Abstract: The present inventors discovered that stable and highly concentrated IgM solutions can be prepared by using, as an additive, a compound comprising a polyvalent cationic ion, such as magnesium chloride or arginine hydrochloride, to suppress IgM aggregation in solutions.Type: ApplicationFiled: July 24, 2009Publication date: November 19, 2009Inventors: Tomoyuki Igawa, Yasuo Sekimori
-
Publication number: 20090082266Abstract: To provide a GLP-1 analogue long-acting prophylactic or therapeutic agent for diabetes, diabetic complications and/or obesity due to diabetes which provides an extended half-life of a GLP-1 analogue in the blood to prevent frequent administration, and is biodegradable and safe. The present invention provides a conjugate obtained by binding, to a GLP-1 analogue into which a mercapto group is incorporated, water soluble hyaluronic acid modification product obtained by incorporating a substituent via an amide bond to the carboxyl group of glucuronic acid portion of hyaluronic acid as a derivative thereof, using a specific condensing agent in an aprotic polar solvent; and a prophylactic or therapeutic agent having a durable blood glucose lowering effect for diabetes, diabetic complications or obesity.Type: ApplicationFiled: March 8, 2006Publication date: March 26, 2009Inventors: Teruo Nakamura, Tatsuya Kato, Hideyuki Togawa, Kenji Yasugi, Hiroko Konishi, Yasuo Sekimori, Tsuyoshi Shimoboji
-
Publication number: 20090061485Abstract: The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed.Type: ApplicationFiled: December 22, 2004Publication date: March 5, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20080166756Abstract: The present invention relates to a method of producing a recombinant protein particularly an antibody using a cell in which the function of a fucose transporter is inhibited. According to the present invention, a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed is provided.Type: ApplicationFiled: October 26, 2005Publication date: July 10, 2008Inventors: Masayuki Tsuchiya, Shigeyuki IIjima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20070249812Abstract: The present inventors examined use of citric acid buffers for suppressing cryoprecipitation of IgM at a pH range and salt concentration suitable for storing IgM. As a result, the present inventors discovered that citric acid buffers significantly suppress cryoprecipitation.Type: ApplicationFiled: October 8, 2004Publication date: October 25, 2007Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Akira Hayasaka, Tomoyuki Igawa, Yasuo Sekimori
-
Publication number: 20070212346Abstract: The present inventors discovered that stable and highly concentrated IgM solutions can be prepared by using, as an additive, a compound comprising a polyvalent cationic ion, such as magnesium chloride or arginine hydrochloride, to suppress IgM aggregation in solutions.Type: ApplicationFiled: October 8, 2004Publication date: September 13, 2007Inventors: Tomoyuki Igawa, Yasuo Sekimori
-
Publication number: 20060276634Abstract: The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.Type: ApplicationFiled: August 3, 2006Publication date: December 7, 2006Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Teruo Nakamura, Yasuo Sekimori, Minoru Machida, Hiromitsu Kawata, Hajime Miyamoto
-
Publication number: 20060246456Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: ApplicationFiled: June 18, 2004Publication date: November 2, 2006Inventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu
-
Publication number: 20050148763Abstract: The object of the present invention is to provide PTH or a PTH derivative, which is modified to attain increased bioavailability without losing PTH activity and to have a reduced risk of side effects. PEG conjugation to PTH or a PTH derivative increases the bioavailability while maintaining PTH activity and also reduces side effects.Type: ApplicationFiled: February 3, 2003Publication date: July 7, 2005Inventors: Yasuo Sekimori, Teruo Nakamura, Masaru Shimizu
-
Publication number: 20040082765Abstract: The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.Type: ApplicationFiled: April 16, 2003Publication date: April 29, 2004Inventors: Teruo Nakamura, Yasuo Sekimori, Minoru Machida, Hiromitsu Kawata, Hajime Miyamoto